Evidence map›Paper›PMID 30126250›Full record

ArticleAntioxidants (Basel, Switzerland)2018

Inhibitory Effects of Auraptene and Naringin on Astroglial Activation, Tau Hyperphosphorylation, and Suppression of Neurogenesis in the Hippocampus of Streptozotocin-Induced Hyperglycemic Mice.

Satoshi Okuyama, Tatsumi Nakashima, Kumi Nakamura, Wakana Shinoka, Maho Kotani, Atsushi Sawamoto, Mitsunari Nakajima, Yoshiko Furukawa

Open access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 35 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Effects ofAntioxidants (Basel, Switzerland) · 2023
    Article
  10. Review
  11. Article
  12. Naringin Regulates Microglia BV-2 Activation and Inflammation via the JAK/STAT3 Pathway.Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Satoshi OkuyamaDepartment of Pharmaceutical Pharmacology, College of Pharmaceutical Sciences, Matsuyama University, 4-2 Bunkyo-cho, Matsuyama, Ehime 790-8578, Japan. sokuyama@g.matsuyama-u.ac.jp.
Tatsumi NakashimaDepartment of Pharmaceutical Pharmacology, College of Pharmaceutical Sciences, Matsuyama University, 4-2 Bunkyo-cho, Matsuyama, Ehime 790-8578, Japan. mu.yakuri.009@gmail.com.
Kumi NakamuraDepartment of Pharmaceutical Pharmacology, College of Pharmaceutical Sciences, Matsuyama University, 4-2 Bunkyo-cho, Matsuyama, Ehime 790-8578, Japan. mu.yakuri.008@gmail.com.
Wakana ShinokaDepartment of Pharmaceutical Pharmacology, College of Pharmaceutical Sciences, Matsuyama University, 4-2 Bunkyo-cho, Matsuyama, Ehime 790-8578, Japan. mu.yakuri.010@gmail.com.
Maho KotaniDepartment of Pharmaceutical Pharmacology, College of Pharmaceutical Sciences, Matsuyama University, 4-2 Bunkyo-cho, Matsuyama, Ehime 790-8578, Japan. mu.yakuri.011@gmail.com.
Atsushi SawamotoDepartment of Pharmaceutical Pharmacology, College of Pharmaceutical Sciences, Matsuyama University, 4-2 Bunkyo-cho, Matsuyama, Ehime 790-8578, Japan. asawamot@g.matsuyama-u.ac.jp.
Mitsunari NakajimaDepartment of Pharmaceutical Pharmacology, College of Pharmaceutical Sciences, Matsuyama University, 4-2 Bunkyo-cho, Matsuyama, Ehime 790-8578, Japan. mnakajim@g.matsuyama-u.ac.jp.
Yoshiko FurukawaDepartment of Pharmaceutical Pharmacology, College of Pharmaceutical Sciences, Matsuyama University, 4-2 Bunkyo-cho, Matsuyama, Ehime 790-8578, Japan. furukawa@g.matsuyama-u.ac.jp.ORCID 0000-0003-1233-3526
Matsuyama University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Auraptene, a citrus-related compound, exerts anti-inflammatory effects in peripheral tissues, and we demonstrated these effects in the brains of a lipopolysaccharide-injected systemic inflammation animal model and a brain ischemic mouse model. Naringin, another citrus-related compound, has been shown to exert antioxidant effects in several animal models. Hyperglycemia induces oxidative stress and inflammation and causes extensive damage in the brain; therefore, we herein evaluated the anti-inflammatory and other effects of auraptene and naringin in streptozotocin-induced hyperglycemic mice. Both compounds inhibited astroglial activation and the hyperphosphorylation of tau at 231 of threonine in neurons, and also recovered the suppression of neurogenesis in the dentate gyrus of the hippocampus in hyperglycemic mice. These results suggested that auraptene and naringin have potential effects as neuroprotective agents in the brain.

Indexed as

anti-inflammationanti-oxidationauraptenehyperglycemianaringinneurogenesistau phosphorylation

Identifiers

PMID30126250
PMCPMC6115810
OpenAlexW2886025455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.